Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Article
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
[powerpress]
Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Article
Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Article
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
[powerpress]
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Article
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.
[powerpress]
Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Article
Drs. Ross Camidge and Corey Langer give their views on more widespread availability of new mutation tests.
[powerpress]
Dr. Phil Bonomi, Rush University: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Article
Dr. Phil Bonomi, from Rush University, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Article
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
[powerpress]
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Article
Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
[powerpress]
Dr. Leighl on Maintenance Therapy as Last Highlight of Lung Cancer from 2012
Article
The last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta.
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Article
Drs. Ross Camidge and Corey Langer provide their perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]